Addition of aldosterone receptor blocker to dual renin-angiotensin-aldosterone blockade leads to limitation of tubulointerstitial injury of kidney.
Tylicki
L
L
Rutkowski
P
P
Renke
M
M
Rutkowski
B
B
D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use; D001565:Benzoates / Q000627:therapeutic use; D017315:Cilazapril / Q000627:therapeutic use; D018592:Cross-Over Studies; D004359:Drug Therapy, Combination; D006801:Humans; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use*; D009395:Nephritis, Interstitial / Q000188:drug therapy*; D012084:Renin-Angiotensin System / Q000187:drug effects; D013148:Spironolactone / Q000627:therapeutic use; D000077333:Telmisartan
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D001562:Benzimidazoles; D001565:Benzoates; D000451:Mineralocorticoid Receptor Antagonists; D017315:Cilazapril; D013148:Spironolactone; D000077333:Telmisartan